secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001559053-25-000029
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q2 net loss $125.8M; prasinezumab to enter Phase 3 by end 2025
-----------------------------------------------------------------------

- Net loss $125.8M vs income $66.9M last year; includes $32.6M restructuring charge and $44.9M non-cash tax allowance.
- Revenue $4.4M, down from $132.0M YoY; cash $372.3M with no debt; FY 2025 cash burn guidance $170-178M.
- Partner Roche plans Phase 3 start for prasinezumab in early Parkinson's by end 2025; peak sales potential >$3B.
- Initial Phase 1 data for PRX012 in Alzheimer's expected August 2025; up to $105M milestones possible in 2026.
- Prothena to hold EGM by year-end to vote on share capital reduction for potential share redemption program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905325000029/0001559053-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905325000029/prta-20250804.htm
  HTML page:      https://secwatch.observer/filing/0001559053-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer